
Etavopivat for sickle cell disease submitted to FDA and EMA
Key Takeaways
- Novo Nordisk has filed etavopivat, an oral once-daily PKR activator, with the FDA and EMA for SCD in patients aged 12 years and older; regulatory decisions are expected in 2027.
- In phase 3 HIBISCUS, etavopivat added to standard care reduced annualized VOCs by 27%, delayed the first VOC by about 4 months, and produced a >1 g/dL hemoglobin increase at week 24 in 48.7% of patients vs 7.2% with placebo.
Novo Nordisk filed etavopivat for SCD in patients aged 12+, backed by phase 3 HIBISCUS data showing a 27% drop in vaso-occlusive crises vs placebo.
Adolescents and adults with sickle cell disease (SCD) moved closer to a new oral, once-daily option after Novo Nordisk submitted etavopivat to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for patients aged 12 years and older.¹ Both agencies are expected to reach decisions in 2027.¹
The filings rest on the phase 3 HIBISCUS trial, in which etavopivat reduced the annualized rate of vaso-occlusive crises (VOCs) by 27% compared with placebo when added to standard care.¹˒² Martin Holst Lange, executive vice president, chief scientific officer, and head of research and development at Novo Nordisk, noted that VOCs profoundly affect daily life and that treatment options remain limited.¹ "We are hopeful that etavopivat can provide a new disease-modifying treatment option," he said.¹
HIBISCUS phase 3 trial design and etavopivat efficacy in SCD
HIBISCUS (NCT04624659) is a randomized, double-blind, placebo-controlled phase 2/3 trial that enrolled approximately 440 patients aged 12 years and older with SCD who had 2 to 15 VOCs in the previous 12 months.¹ After a 12-week phase 2 interim analysis guided dose selection, 385 participants were randomly assigned to etavopivat 400 mg once daily or placebo for 52 weeks in the phase 3 portion.²
Etavopivat met both co-primary endpoints.² Beyond the 27% reduction in annualized VOCs at week 52, median time to first VOC was 38.4 weeks with etavopivat vs 20.9 weeks with placebo, a delay of roughly 4 months.² At week 24, 48.7% of etavopivat recipients achieved a hemoglobin increase greater than 1 g/dL, compared with 7.2% of placebo recipients (adjusted rate difference, 41.2%).² In an exploratory analysis, etavopivat also reduced the risk of blood transfusion.² The company reported that the drug appeared well tolerated, with a topline safety profile consistent with earlier studies; specific adverse event rates have not been released.²
Sickle cell disease burden and current treatment gaps
SCD is driven by polymerization of mutated sickle hemoglobin (HbS), producing the hallmark features of hemolytic anemia and VOCs.¹ An estimated 8 million people are affected worldwide, including approximately 100,000 in the US and 110,000 in Europe, and life expectancy is shortened by about 20 years relative to the general population.¹ Complications include acute chest syndrome, stroke, multiorgan damage, and cognitive impairment.²
Despite hydroxyurea, transfusion, stem cell transplant, and gene therapy, unmet need persists because of limited access, variable response, toxicity, cost, and incomplete control of hemolysis and vaso-occlusion.⁴ An oral agent targeting both anemia and crisis frequency could address part of that gap.
How etavopivat works as a PKR activator in sickle cell disease
Etavopivat is an investigational, selective activator of pyruvate kinase red blood cell isozyme (PKR).¹ Activating PKR lowers 2,3-diphosphoglycerate (2,3-DPG), which increases hemoglobin-oxygen affinity and reduces sickling, and raises adenosine triphosphate (ATP) production, which supports membrane integrity and red cell survival.¹˒⁴ In a phase 1 open-label cohort, 11 of 15 patients (73%) receiving 400 mg daily for 12 weeks had a hemoglobin increase greater than 1 g/dL, hemolysis markers declined, and adverse events were mostly grade 1 or 2.³ The FDA has granted etavopivat Fast Track, Rare Pediatric Disease, and Orphan Drug designations, and the European Commission has granted orphan designation.¹
Etavopivat evidence gaps and ongoing HIBISCUS 2 and FLORAL studies
The HIBISCUS findings are topline; detailed results have not yet been presented or published, so detailed safety data and outcomes specific to adolescents cannot yet be evaluated.¹ A 27% relative reduction in VOCs is a moderate effect, and clinicians will want to see absolute event rates and whether hemoglobin gains translate into less end-organ damage over time. Because HIBISCUS enrolled only patients aged 12 years and older, no efficacy data exist for younger children.¹
HIBISCUS 2 (NCT06612268), a 52-week phase 3b trial, is expected to enroll 510 patients aged 12 years and older, and the FLORAL open-label extension (NCT06609226) is collecting long-term safety data.¹
References
1. Novo. Novo submits etavopivat, an investigational once-daily therapy for adolescents and adults living with sickle cell disease, to the FDA and EMA for approval. News release. PR Newswire. November 13, 2026. Accessed November 16, 2026. https://www.prnewswire.com/news-releases/novo-submits-etavopivat-an-investigational-once-daily-therapy-for-adolescents-and-adults-living-with-sickle-cell-disease-to-the-fda-and-ema-for-approval-302938346.html
2. Novo Nordisk. Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis events and improving haemoglobin response in sickle cell disease. News release. April 20, 2026. Accessed November 16, 2026. https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916533
3. Saraf SL, Hagar R, Idowu M, et al. Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease. Blood Adv. 2024;8(16):4459-4475. doi:10.1182/bloodadvances.2023012467
4. Musallam KM, Andemariam B. Pyruvate kinase activation in the management of thalassemia and sickle cell disease. Hemoglobin. 2026;50(4):308-320. doi:10.1080/03630269.2026.2682386
Related to this article








